➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Express Scripts

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Patent: 9,187,749

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,187,749
Title:Methods for modulating factor 12 expression
Abstract: Disclosed herein are methods for decreasing Factor 12 and treating or preventing inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 12 include hereditary angioedema (HAE). Methods for inhibiting Factor 12 can also be used as a prophylactic treatment to prevent individuals at risk for developing an inflammatory condition, such as, hereditary angioedema.
Inventor(s): Bhattacharjee; Gourab (San Diego, CA), Revenko; Alexey (San Diego, CA), MacLeod; Robert A. (San Diego, CA)
Assignee: Isis Pharmaceuticals, Inc. (Carlsbad, CA)
Application Number:14/124,621
Patent Claims:see list of patent claims

Details for Patent 9,187,749

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Csl Behring Gmbh BERINERT human c1-esterase inhibitor KIT 125287 1 2011-12-22   Start Trial Isis Pharmaceuticals, Inc. (Carlsbad, CA) 2031-06-10 search
Dyax Corp. KALBITOR ecallantide INJECTABLE; INJECTION 125277 001 2009-12-01   Start Trial Isis Pharmaceuticals, Inc. (Carlsbad, CA) 2031-06-10 RX Orphan search
Viropharma Biologics, Inc. CINRYZE human c1-esterase inhibitor INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 125267 1 2008-12-01   Start Trial Isis Pharmaceuticals, Inc. (Carlsbad, CA) 2031-06-10 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.